–
ArriVent BioPharma, Inc.
Metrics score locked — part of Premium
FY22
FY23
FY24
FY25
FY22 – FY25
(positive)
millions USD
FY22:
FY23:
–
FY24:
–
FY25:
–
(positive)
Change from FY22 to FY25
millions USD
FY22:
−36.9
FY23:
−74.6
FY24:
−94.3
FY25:
−178
(positive)
Change from FY22 to FY25
millions USD
FY22:
−36.9
FY23:
−74.6
FY24:
−94.3
FY25:
−178
(positive)
Change from FY22 to FY25
millions USD
FY22:
−36.9
FY23:
−69.3
FY24:
−80.5
FY25:
−166
(positive)
Change from FY22 to FY25
millions USD
FY22:
−36.9
FY23:
−69.3
FY24:
−80.5
FY25:
−166
All amounts in millions USD FY22: figures supplemented from Twelve Data because the SEC filings do not reach back this far.